Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
April 15, 2022
Date of Patent:
January 10, 2023
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
April 11, 2022
Date of Patent:
January 3, 2023
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
Abstract: The invention relates to a HLA-B27 Fc open conformer or a HLA-B27 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B27 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B27 Fc open conformer and immune checkpoint inhibitors.
Type:
Grant
Filed:
August 4, 2017
Date of Patent:
November 1, 2022
Assignees:
UNIVERSITÄT BASEL, UNIVERSITÄT ZURICH
Inventors:
Osiris Marroquin Belaunzaran, Christoph Renner, Ulf Petrausch
Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
Type:
Grant
Filed:
February 13, 2019
Date of Patent:
October 18, 2022
Assignees:
GANYMED PHARMACEUTICALS GMBH, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Inventors:
Ugur Sahin, Özlem Tureci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Woll, Gabriela-Elena Oprea
Abstract: A delivery vehicle, for delivering a pharmaceutically active agent or a marker to a cell, comprising a ligand binding portion specific for a Fas Ligand, and a carrier for the pharmaceutically active agent or marker.
Type:
Grant
Filed:
July 21, 2010
Date of Patent:
June 28, 2022
Assignee:
Queen Mary & Westfield College
Inventors:
Davidson Day Ateh, Joanne Elizabeth Martin
Abstract: The disclosure of the preset invention relates to a new method for preventing or treating tumor progression or tumor recurrence comprising administering to a subject in need thereof a therapeutically effective amount of an agent disrupting Musashi-1 (MSI1)/Argonaute 2 (AGO2) interaction. A composition or pharmaceutical composition for preventing or treating tumor progression or tumor recurrence is also provided, which comprises an agent disrupting Musashi-1 (MSI1)/Argonaute 2 (AGO2) interaction.
Abstract: Disclosed herein are improved compositions and methods involved in treating hematologic cancers, i.e., cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. The compositions comprise complexes containing albumin-containing nanoparticles (e.g., ABRAXANE® nanoparticles) and antibodies. The compositions are used to effect hematologic cancer cell death.
Type:
Grant
Filed:
February 10, 2017
Date of Patent:
June 7, 2022
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Abstract: The present application provides a synthetic peptide with an amino acid sequence SEQ ID NO: 1 plus a cysteine at its N-terminal, an artificial antigen, an antibody specific to a human EHD2, a method for preparing an antibody specific to the human EHD2 protein and adopted to an immunohistochemical method for EHD2 detection as well as cancer diagnosing and prognosing.
Type:
Grant
Filed:
March 4, 2019
Date of Patent:
April 5, 2022
Assignee:
TIANJIN YINGSHIBO TECHNOLOGY DEVELOPMENT CO., LTD.
Abstract: The presently disclosed subject matter is directed to a method of treating cancer, such as (but not limited to) metastatic bladder and breast cancer. The disclosed method comprises using two treatment modalities to synergistically treat primary and secondary tumor cells in a subject. The first element of the method comprises administering a therapeutically effective amount of a plasmonics-active metal nanoparticle to a subject comprising a primary cancer and a distant metastatic site, wherein the nanoparticle concentrates at the primary cancer. The method further comprises exposing the subject to photon radiation at the site of the primary cancer. The second element of the disclosed method comprises administering a therapeutically effective amount of an immune checkpoint modulator to the subject. The synergistic combination provides a rapid, safe, and effective treatment of local and distant lesions, better than each modality alone.
Type:
Grant
Filed:
December 22, 2017
Date of Patent:
March 1, 2022
Assignee:
Duke University
Inventors:
Tuan Vo-Dinh, Brant A. Inman, Paolo Maccarini, Greg Palmer, Yang Liu, Douglas Weitzel
Abstract: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-?B activity. The modulators may be used, for example, in the treatment of NF-?B-mediated diseases, conditions, and injuries.
Abstract: The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.
Type:
Grant
Filed:
January 25, 2016
Date of Patent:
January 25, 2022
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: A cancer therapeutic agent according to an embodiment of the present invention contains, as active ingredients, IL-18 and one or more antibodies selected from the group consisting of an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-CD25 antibody, an anti-CD33 antibody, and an anti-CD52 antibody.
Type:
Grant
Filed:
August 7, 2015
Date of Patent:
January 11, 2022
Assignees:
Medical Research and Development Corporation, Foundation for Biomedical Research and Innovation
Inventors:
Haruki Okamura, Kyosuke Yamanishi, Wen Li
Abstract: The present invention relates to a method for the accurate, rapid and sensitive detection of breast or ovarian cancers from body fluid samples of a mammalian subject and related assay, kits and peptides suitable for such a method.
Type:
Grant
Filed:
June 13, 2018
Date of Patent:
December 7, 2021
Assignee:
BARD1 LIFE SCIENCES LIMITED
Inventors:
Solomzi Makohliso, Irmgard Irminger-Finger, Fernando Herrera
Abstract: Provided is a rabbit monoclonal antibody to acetylated mouse BubR1 and a preparation method therefor and, more particularly, provides the use of the monoclonal antibody in a method for measuring the activity of cell division checkpoints on the basis of a degree of acetylation of BubR1, a method for detecting a tumor disease on the basis of aberrant cell division, a method for diagnosing cancer, a method for screening anti-cancer agents, or a method for regulating a cell division cycle.
Type:
Grant
Filed:
January 20, 2017
Date of Patent:
November 30, 2021
Assignee:
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventors:
Hyunsook Lee, Mi-Sun Kwon, Inai Park, Hyeon-Jong Kim
Abstract: The invention relates to combinations of peptides carrying T-cell epitopes of the antigen preprocalcitonin, presented by the MHC. These peptides can be used in anti-tumour immunotherapy.
Type:
Grant
Filed:
July 4, 2016
Date of Patent:
November 23, 2021
Assignees:
Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale, Université Paris-Saclay
Abstract: Early detection of tumors is a major determinant of survival of patients suffering from tumors, including bladder tumors. Members of the BTM or UBTM family can be highly and consistently accumulated in bladder tumor tissue and other tumor tissue, and/or can be accumulated in urine of patients, and thus are markers for bladder and other types of cancer. In certain embodiments, BTMs or UBTMs can accumulate in the urine, and detection of UBTM family members can be an effective diagnostic approach. In some embodiments, quantitative PCR methods have advantages over microarray methods. In other embodiments, detection and quantification of a plurality of BTMs or UBTMs can increase the sensitivity and specificity of detection of bladder cancer, and therefore provides methods for determining the stage and type of bladder cancer. Kits provide easy, convenient ways for carrying out the methods of this invention.
Type:
Grant
Filed:
July 22, 2005
Date of Patent:
September 28, 2021
Assignee:
Pacific Edge Limited
Inventors:
Parry John Guilford, Natalie Jane Kerr, Robert Craig Pollock
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
March 10, 2020
Date of Patent:
September 14, 2021
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
Abstract: The present invention relates to the use of BAG3 antibodies as a medicament, in particular for use in the treatment of pancreatic tumours or other pathologies of an immune, inflammatory, neoplastic and/or degenerative nature.
Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
Type:
Grant
Filed:
March 15, 2019
Date of Patent:
August 24, 2021
Assignee:
Five Prime Therapeutics, Inc.
Inventors:
Thomas Brennan, David Bellovin, David Busha, Barbara Sennino